Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonepcizumab + ranibizumab
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Sonepcizumab + ranibizumab is a combination of two biologic drugs under investigation primarily for the treatment of neovascular eye diseases, including neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV)[1][5]. Sonepcizumab is a humanized monoclonal antibody targeting sphingosine-1-phosphate, which is implicated in angiogenesis and vascular leakage, although clinical development substantially focused on oncology and ophthalmology. Ranibizumab is a recombinant humanized monoclonal antibody fragment (Fab) that inhibits vascular endothelial growth factor A (VEGF-A), a key driver of pathological blood vessel growth and increased vascular permeability in ocular diseases[4][6]. The rationale for combination therapy includes broader inhibition of angiogenic pathways and a potential for superior anatomic and functional outcomes compared to anti-VEGF-A monotherapy[1][5].
- Brand names
- Lucentis
- Other names
- iSONEP + Lucentis
02
Targets
VEGFA (Vascular endothelial growth factor A)S1P (Site-1 protease)
Beyond the preview
Go deeper on sonepcizumab + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonepcizumab + ranibizumab.